Fortrea (FTRE) Expected to Release Earnings on Wednesday

Fortrea (NASDAQ:FTRE) will likely be releasing its Q2 2026 results before the market opens on Wednesday, July 29th. Analysts expect the company to post earnings of $0.18 per share and revenue of $647.53 million for the quarter. Interested persons can check the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Wednesday, July 29, 2026 at 8:00 AM ET.

Fortrea (NASDAQ:FTRE) last announced its quarterly earnings data on Tuesday, May 5th. The company reported $0.16 EPS for the quarter, beating the consensus estimate of $0.03 by $0.13. The firm had revenue of $636.50 million for the quarter, compared to analyst estimates of $628.50 million. Fortrea had a positive return on equity of 9.51% and a negative net margin of 16.50%. On average, analysts expect Fortrea to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Fortrea Stock Performance

NASDAQ:FTRE opened at $19.52 on Monday. The company has a market capitalization of $1.85 billion, a price-to-earnings ratio of -3.98, a PEG ratio of 0.59 and a beta of 2.03. The business has a 50 day moving average of $16.42 and a 200 day moving average of $13.73. The company has a debt-to-equity ratio of 1.98, a current ratio of 0.95 and a quick ratio of 0.95. Fortrea has a 1-year low of $5.26 and a 1-year high of $20.19.

Analyst Ratings Changes

FTRE has been the topic of several research reports. Barclays lifted their price target on shares of Fortrea from $16.00 to $18.00 and gave the stock an “equal weight” rating in a research note on Wednesday, June 24th. TD Cowen reaffirmed a “buy” rating on shares of Fortrea in a research note on Wednesday, May 6th. Robert W. Baird set a $20.00 target price on shares of Fortrea in a report on Wednesday, May 6th. Zacks Research raised shares of Fortrea from a “hold” rating to a “strong-buy” rating in a research note on Monday, July 6th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Fortrea in a research report on Friday, July 17th. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Fortrea currently has a consensus rating of “Moderate Buy” and a consensus price target of $17.75.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. Osaic Holdings Inc. boosted its position in Fortrea by 74.3% during the 2nd quarter. Osaic Holdings Inc. now owns 6,844 shares of the company’s stock valued at $38,000 after buying an additional 2,918 shares during the period. Tower Research Capital LLC TRC boosted its holdings in shares of Fortrea by 137.0% during the second quarter. Tower Research Capital LLC TRC now owns 8,713 shares of the company’s stock worth $43,000 after purchasing an additional 5,036 shares during the period. Toronto Dominion Bank purchased a new stake in shares of Fortrea during the fourth quarter worth about $51,000. EverSource Wealth Advisors LLC increased its holdings in Fortrea by 662.9% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 11,963 shares of the company’s stock valued at $59,000 after purchasing an additional 10,395 shares during the period. Finally, Franklin Resources Inc. bought a new position in Fortrea during the 2nd quarter valued at approximately $60,000.

About Fortrea

Fortrea, Inc is a global contract development and manufacturing organization (CDMO) that provides integrated solutions for pharmaceutical and biotechnology companies. Established as a spin-off from Thermo Fisher Scientific’s Pharma Services business in October 2023, Fortrea leverages a legacy of scientific expertise and manufacturing scale to support drug development from early-stage research through commercial production. The company’s comprehensive offerings address the complex needs of both small-molecule and biologics programs, making it a single source for clients seeking to accelerate timelines and manage costs.

Fortrea’s core services encompass analytical and formulation development, process optimization, clinical and commercial manufacturing, and packaging services.